# Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

> **NCT00415051** · PHASE2 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 20 (actual)

## Conditions studied

- Rift Valley Fever

## Interventions

- **BIOLOGICAL:** RVF MP-12

## Key facts

- **NCT ID:** NCT00415051
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-05
- **Final completion:** 2009-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415051, "Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00415051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*